F-STAR THERAPEUTICS INC (FSTX)
US30315R1077 - Common Stock
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
F-star Therapeutics stock surges as buyer Sino Biopharma gains CFIUS approval
F-star Therapeutics (FSTX) jumped 16% in premarket trading after its sale to Sino Biopharmaceuticals (SBHMY) won approval from the Committee on Foreign Investment in the U.S.CFIUS...
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer...
CDTX, PTGX and TAST among premarket gainers (NASDAQ:FSTX)
ThredUp TDUP +17% on Q4 earnings.Protagonist Therapeutics (PTGX) +20% on positive topline results for Phase 2b FRONTIER 1 clinical trial of Oral IL-23 Receptor Antagonist JNJ-2113...
F-star Therapeutics stock surges on report sale to Sino Biopharma close to CFIUS Ok
F-star Therapeutics (FSTX) jumped 15% in premarket trading on a report that its sale to Sino Biopharmaceuticals (SBHMY) is set to gain approval from the Committee on Foreign Investment...
Sino Biopharm Wins CFIUS Approval for $161 Million F-Star Deal
Sino Biopharmaceutical Ltd.’s invoX Pharma unit has won approval from the Committee on Foreign Investment in the United States to proceed with its $161 million takeover of F-star Therapeutics Inc.
F-star Therapeutics jumps as it extends walk date with buyer to finalize CFIUS agreement
F-star Therapeutics (FSTX) soared 18% after announcing that itss extended the termination date for its planned merger with invoX Pharma again as it needs additional time to finalize CFIUS.
F-star Therapeutics deal termination date with Sino Biopharma extended again
F-star Therapeutics (FSTX) rose 2.3% in premarket trading after announcing that it's extended the end date for its planned merger with invoX Pharma again as it continues to negotiate...
F-star Therapeutics stock gains as buyer Sino Biopharma cancels Shanghai listing
F-star Therapeutics (FSTX) rose 6% as buyer Sino Pharmaceutical (SBHMY) canceled a planned Shanghai stock exchange listing.The termination of the planned listing on the exchange for...
invoX Pharma and F-star Therapeutics issue Joint Statement
invoX Pharma and F-star Therapeutics issue Joint Statement
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX...
FSTX stock rebounds as merger deadline extends again (NASDAQ:FSTX)
Shares of F-star Therapeutics (FSTX) surged ~43% on Friday as investors reacted to an announcement to extend the company's merger deal with invoX Pharma. Read the full story here.
FSTX stock sinks as CFIUS objects Sino-Biopharma deal (NASDAQ:FSTX)
U.K.-based biotech F-star Therapeutics (FSTX) shed ~37% pre-market Thursday in reaction to a filing indicating that regulatory watchdog The Committee on Foreign Investment (CFIUS) issued...
